15 completed, 4 unknown, 1 not yet recruiting, 1 recruiting. 22 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 15, Unknown 4, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Diabetic Polyneuropathy: new trials by email Literature Review of Diabetic Polyneuropathy trials Research Report on Diabetic Polyneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy DLBS1033, Placebo Comparator: Placebo + Standard Therapy - Diabetic Polyneuropathy, Peripheral Nervous System Diseases | Phase 2 / Phase 3 | Not yet recruiting | Universitas Sebelas Maret | 34 | 2026-03-01 | 2026-03-16 |
| Peripheral Magnetic Stimulation With Balance Training to Decrease Fall Risks in Diabetic Polyneuropathy Peripheral magnetic stimulation, Balance training, Sham stimulation - Diabetic Polyneuropathy | Phase 2 | Recruiting | Queen Savang Vadhana Memorial Hospital, Thailand | 40 | 2025-06-10 | 2026-08-18 |
| A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy Eptinezumab, Placebo - Diabetic Polyneuropathy | Phase 2 | Withdrawn | Mayo Clinic | 2025-01-01 | 2025-03-06 | |
| The Effect of Alpha Lipoid Acid and Vitamin B Preparation on Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patient Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA - Diabetic Polyneuropathy | Phase 2 | Unknown | Universiti Sains Malaysia | 76 | 2024-05-27 | 2024-08-23 |
| A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract Fermented Deglycyrrhizinated Licorice, Non-fermented Deglycyrrhizinated Licorice - Diabetic Polyneuropathy | Phase 2 | Completed | Helwan University | 83 | 2023-01-10 | 2025-08-29 |
| Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain Lidocaine HCl, Normal saline - Postherpetic Neuralgia, Diabetic Polyneuropathy | Phase 2 | Unknown | Seoul National University Hospital | 44 | 2015-08-01 | 2015-11-05 |
| Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy calcined magnesia, Ezetimibe/simvastatin, Rosuvastatin - Oxidative Stress, Diabetic Polyneuropathy | Phase 2 | Completed | University of Guadalajara | 74 | 2012-02-01 | 2014-05-06 |
| Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis Magnetic Marker Imaging (MMI) with Magma 3D system - Diabetic Polyneuropathy, Diabetic Gastroparesis | Phase 2 | Completed | Martin-Luther-Universität Halle-Wittenberg | 50 | 2012-01-01 | 2012-09-05 |
| Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy Sham device, NormaTec PCD (Peristaltic Pulse PCD) - Diabetic Polyneuropathy | Phase 1 / Phase 2 | Unknown | NormaTec Industries LP | 60 | 2010-10-01 | 2012-04-20 |
| The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study Rosuvastatin, Placebo - Diabetic Polyneuropathy | Phase 2 | Completed | Alejandra Guillermina Miranda Diaz | 34 | 2010-02-01 | 2012-06-20 |
| Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy SB-509, Saline - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Sangamo Therapeutics | 170 | 2009-11-01 | 2022-05-23 |
| Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Capsaicin, placebo - Diabetic Polyneuropathy | Phase 2 / Phase 3 | Completed | Thammasat University | 33 | 2009-10-01 | 2012-05-09 |
| Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic GRT6005, MS Continus®, Placebo - Diabetic Polyneuropathy | Phase 2 | Completed | Tris Pharma, Inc. | 90 | 2009-04-01 | 2021-07-15 |
| Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 SB-509, Placebo - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Sangamo Therapeutics | 23 | 2008-01-01 | 2012-11-01 |
| Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain ABT-894, placebo, Duloxetine - Diabetic Neuralgia, Diabetic Neuropathies | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 280 | 2007-08-01 | 2013-01-23 |
| Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy SB-509, Placebo - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Sangamo Therapeutics | 91 | 2007-05-01 | 2012-11-01 |
| Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). placebo, RWJ-333369 (carisbamate) - Diabetic Neuropathy, Painful, Diabetic Neuralgia | Phase 2 | Completed | SK Life Science, Inc. | 132 | 2007-03-01 | 2018-05-01 |
| Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy SB-509, Normal Saline - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Sangamo Therapeutics | 110 | 2006-11-01 | 2012-11-01 |
| Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy Placebo, MCC-257 - Diabetic Polyneuropathy | Phase 2 | Completed | Tanabe Pharma Corporation | 420 | 2006-03-01 | 2007-12-28 |
| Effect of C-Peptide on Diabetic Peripheral Neuropathy C-peptide - Diabetes Mellitus, Type 1, Diabetic Polyneuropathy | Phase 2 | Completed | Creative Peptides Sweden Inc. | 180 | 2003-10-01 | 2006-01-19 |
Showing 20 of 22. Sign in to see all of them.
Diabetic Neuropathies (22) · Diabetes Mellitus (5) · Diabetes Mellitus, Type 1 (5) · Diabetes Mellitus, Type 2 (4) · Diabetes Complications (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Neuralgia (2) · Peripheral Nervous System Diseases (2) · Diabetic Foot (1) · Mitochondrial Diseases (1) · Neuralgia, Postherpetic (1) · Pain (1) · Ulcer (1)
Endocrine System Diseases (22) · Nervous System Diseases (22) · Neuromuscular Diseases (22) · Diabetes Complications (20) · Peripheral Nervous System Diseases (20) · Diabetes Mellitus (17) · Metabolic Diseases (11) · Nutritional and Metabolic Diseases (11) · Glucose Metabolism Disorders (10) · Autoimmune Diseases (5) · Immune System Diseases (5) · Pathological Conditions, Signs and Symptoms (4) · Neurologic Manifestations (3) · Signs and Symptoms (3) · Congenital Abnormalities (2)
Rosuvastatin Calcium (2) · Saline Solution (2) · 3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo(3.2.0)heptane (1) · C-Peptide (1) · Capsaicin (1) · DLBS 1033 (1) · Duloxetine Hydrochloride (1) · Ezetimibe, Simvastatin Drug Combination (1) · Lidocaine (1) · Long-Term Synaptic Depression (1) · MCC-257 (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1) · Sodium Chloride (1) · Standard of Care (1) · eptinezumab (1)
Sangamo Therapeutics (4) · AbbVie (prior sponsor, Abbott) (1) · Alejandra Guillermina Miranda Diaz (1) · Creative Peptides Sweden Inc. (1) · Diabetica Solutions Inc. (1) · Helwan University (1) · Martin-Luther-Universität Halle-Wittenberg (1) · Mayo Clinic (1) · NormaTec Industries LP (1) · Queen Savang Vadhana Memorial Hospital, Thailand (1) · SK Life Science, Inc. (1) · Seoul National University Hospital (1) · Tanabe Pharma Corporation (1) · Thammasat University (1) · The Institute for Diabetes Discovery, LLC (1)
United States (9) · Mexico (5) · Germany (3) · Canada (2) · Thailand (2) · Denmark (1) · Egypt (1) · France (1) · Indonesia (1) · Italy (1) · Malaysia (1) · Puerto Rico (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Adolfo D Rodriguez-Carrizalez, PhD, MD (1) · Ahmed Aly Massoud, PhD (1) · Alejandra G Miranda-Diaz, PhD,MD,FACS (1) · Alejandra G. Miranda-Diaz, MD, PhD (1) · C. Mauli Agrawal, Ph.D. (1) · Geannyne Villegas-Rivera, PhD, MD (1) · Jaime Hernandez-Ojeda, MD, PhD (1) · Kevin R Higgins, DPM (1) · Kongkiat Kulkantrakorn, MD (1) · Krisandi Hartanto, MD (1) · Lisa Juntti-Berggren, MD, PhD (1) · Luis M Roman-Pintos, PhD, MD (1)
PMID 15504999, PMID 26290682, PMID 29381569, PMID 41627541
R43DK088634 (1)